A recent study confirmed the 4Kscore accurately predict aggressive prostate cancer. We assessed whether the performance of the 4Kscore Test differed by age or race.
INTRODUCTION AND OBJECTIVES:
A recent study confirmed the 4Kscore accurately predict aggressive prostate cancer. We assessed whether the performance of the 4Kscore Test differed by age or race.
METHODS: 1312 men referred for prostate biopsy made up the cohort for these analyses. Differential calibration by age was assessed using logistic regression with an interaction between age and the 4Kscore Test for the outcome of a Gleason 3+4 cancer. We further categorized patients by age into subgroups of less than 55, 56-69, and 70 or older. The AUC for the 4Kscore Test was calculated in each age subgroup and confidence intervals for the difference in AUCs between groups were estimated. Similar analyses were performed to assess differential calibration and discrimination of the 4Kscore Test in African Americans versus the rest of the cohort. Finally, Decision curve analysis was used to assess the clinical utility of the 4Kscore Test for predicting aggressive prostate cancer within these sub groups of age and race.
RESULTS: Among the cohort, 291 (22%) men were found to have high-grade cancer on prostate biopsy. There was no evidence to suggest a difference in discrimination of high-grade prostate cancer by either age or race, with the difference in confidence intervals surrounding the AUC's overlapping zero. We found evidence of a difference in calibration by age when age was modeled as a continuous score (p¼0.045). However, on sensitivity analysis looking at age categorized, we found no evidence of differential miscalibration (p¼0.15). We found evidence of a difference in calibration by race (p¼0.02), with scores slightly under predicting Gleason 7 cancer among African American men. Decision curve analysis found a higher net benefit for using the 4Kscore Test to decide on the need for biopsy in all of age and race subgroups.
CONCLUSIONS: We found no evidence of differential discrimination of Gleason 7 prostate cancer by age or race. There is some evidence to suggest miscalibration by age and race but this requires further assessment. Decision curve analysis suggests there is a clinical benefit to using the 4Kscore Test to decide on the need for a prostate biopsy in men of all ages and race. METHODS: From 2011 to 2016, patients with elevated PSA and negative prostate biopsies (PB) were included in an open monocentric prospective study after approval of Institutional review board. Each patient had an urinary PCA3 test to assess the risk of PCa with three different nomograms (Prostate Cancer Prevention Trial Risk Calculator (PCPT), PCPT + PCA3, PCPT 2.0). After consultation, decision to perform biopsy was at urologist discretion. A logistic regression analysis was performed to determine predictive factors (PF) for PCa diagnostic at 12 months and 5 years. Success of screening was defined as positive PB in the first year after consultation or no PCa diagnosed at the end of the follow up. While, failure was defined as negative PB in the first year after consultation or PCa diagnosed more than 12 months after consultation.
RESULTS: In our study, 516 patients were included with mean age 64.7 (IQR47_85), mean PSA 8.1ng/mL (0.27_119.8), mean PCA3 score 22 (1_533) and 18.9% had suspicious digital rectal examination. At 12 months, 6 PF of success were found: low PSA ratio (p¼0.08), low prostatic volume (p<0.01), high PSA density (p<0.01), high PCA3 (p<0.01), high PCPT risk (p¼0.04) and high PCPT + PCA3 risk (p<0.01). At 5 years, after primary screening, PCA3 score isolated or integrate in PCPT risk calculator was the only one biological PF of consultation success (PCPT + PCA3 (p<0.01) and PCA3 rates (p<0.01). The rate of success was 46.5% and 94% at 12 months and 5 years respectively after primary screening (figure 1).
CONCLUSIONS: In our study, PCA3 was able to reach a high rate of positive biopsy at 12 months and allowed to avoid 94% of prostate biopsy at 5 years. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e127
